avdoralimab
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 15, 2020 (NCT04333914)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
C5a anaphylatoxin chemotactic receptor inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594463 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04563923 | Phase 2 | Oct 10, 2020 | University of Nice Sophia Antipolis |
| NCT04371367 | Phase 2 | Apr 27, 2020 | Aix-University of Marseille, Innate Pharma |
| NCT04333914 | Phase 2 | Apr 15, 2020 | Centre Leon Berard |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aix-University of Marseille | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Centre Leon Berard | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Innate Pharma | For profit | 1 | 0 | 1 | 2020 |
| University of Nice Sophia Antipolis | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1